Skip to main content
. Author manuscript; available in PMC: 2011 Jul 15.
Published in final edited form as: Clin Cancer Res. 2010 May 12;16(14):3786–3794. doi: 10.1158/1078-0432.CCR-10-0547

Table 6.

Vorinostat pharmacokinetics

Patients Cmax (µmol/L) Tmax (h) T1/2 (h) AUC0–8 (µmol/L × h)
600 mg orally twice daily 1 4.99 2 1.5 14.3
2 3.43 1 2.2 7.8
3 1.97 4 2.3 10.2
Mean 3.46 2.3 2.0 10.8
SD 1.51 1.5 0.4 3.3
1,700 mg orally once daily 1 0.92 0.5 27.7 2.6
2 6.15 1 2.4 26
3 6.40 4 3.2 35.1
Mean 4.49 1.8 11.1 21.2
SD 3.09 1.9 14.4 16.8

Note: T1/2, half-life